Results from Successful Phase 1 Clinical Trial of AMP945
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Amplia and Garvan Enter Into Collaboration Agreement
- AMP945 Improves Survival in Pacnreatic Cancer Model
- App 4E - Preliminary Final Report YE 31 March 2021
- Proposed issue of Securities - ATX
- Amplia Announces $3.8m Share Placement
Later from Amplia Therapeutics
- Quarterly Activities and Cashflow Reports and Presentation
- AGM - Chief Executive Officers Presentatioin
- Phase 2 Trial in First-Line Pancreatic Cancer Patients
- New Garvan Publication Supports Amplia Phase 2 Design
- Amplia Receives $1.1m R&D Tax Incentive
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics